BridgeBio Pharma (BBIO) has shared an announcement.
BridgeBio Pharma, Inc. announced a significant leadership change as Thomas Trimarchi steps up as the new President and Chief Operating Officer, replacing Neil Kumar, Ph.D., who will maintain his role as CEO and director. Trimarchi, with a background in corporate strategy at Regeneron Pharmaceuticals and equity analysis at Goldman Sachs, brings a strong scientific and financial acumen to his new position. The company has issued a press release regarding the appointment but clarifies that this information is not deemed filed for regulatory purposes.
See more insights into BBIO stock on TipRanks’ Stock Analysis page.